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Asthma is the single most common chronic
disease of childhood, affecting > 3 million
children in the United States. In addition, the
burden of childhood asthma has increased
over the past several decades despite the avail-
ability of excellent medications for controlling
chronic symptoms and treating exacerbations.
Moreover, asthma prevalence and morbidity
are disproportionately high among inner-city
children, most of whom are members of racial
minorities. African-American children in the
United States have a higher prevalence of
asthma and greater morbidity as measured by
acute care visits and hospitalizations compared
with white children (Kattan et al. 1997;
Mannino et al. 2002).
The role of the indoor environment in
triggering and exacerbating asthma and other
respiratory symptoms has been documented
in several studies (Daisey et al. 2003;
Engvall et al. 2001; Nafstad et al. 1998;
Perry et al. 2003; Rosenstreich et al. 1997;
Zock et al. 2002; Zureik et al. 2002). High
exposures to dust mite, cockroach, and mold
have all been implicated in producing respi-
ratory illness, such as infections, cough, and
wheeze. Home dampness and the presence
of mold have also been associated with
asthma, cough, and wheeze (Institute of
Medicine 2004).
Dust mites, mold, and cockroach are
indoor allergens and irritants related to home
moisture content, and all are common in
urban dwellings (Eggleston et al. 1999; Perry
et al. 2003; Rosenstreich et al. 1997). High
levels of indoor humidity promote the growth
and survival of dust mites. Cockroaches can
survive for long periods without food, as long
as a water source, such as that from a leaky
pipe, is available. Finally, growth of a number
of indoor molds (Aspergillus species,
Cladosporium, Penicillium, and Stachybotrys)
may be promoted by high indoor humidity or
water damage (Dales and Miller 1999). In
addition to the allergen potential for mold, a
number of fungal by-products, such as volatile
organic compounds and β-1,2-glucans, may
be respiratory irritants (Jaakkola et al. 2005;
Rylander 2005). Inner-city children may be at
increased risk for asthma morbidity due to
exposure to such indoor allergens, because
they often spend a large amount of time
indoors and live in decaying housing stock
that may be prone to water damage.
Previous indoor environmental asthma
interventions focused on decreasing allergen/
irritant exposure by either blocking exposure
(use of dust covers) or reducing burden of spe-
cific allergen (cockroach abatement) (Evans
et al. 1999; Gergen et al. 1999; Morgan et al.
2004; Shapiro et al. 1999; Woodcock et al.
2003). In this pilot program, we explored the
effects of remediation of root causes of indoor
home moisture and mold on asthma morbid-
ity in inner-city children. Our hypothesis was
that use of a home environmental interven-
tion involving construction remediation of
sources of moisture and mold damage would
significantly decrease asthma symptoms and
health care use beyond that achieved by use of
a standard asthma intervention alone.
Materials and Methods
Patients who were at risk for asthma morbidity
as evidenced by previous, recent unscheduled
health care use were targeted for the study.
Patients were recruited during inpatient hospi-
talizations and after primary care visits and
emergency department (ED) visits at Rainbow
Babies and Children’s Hospital. Referrals were
also accepted from a variety of community
sources, including other health clinics, com-
munity health fairs, and general advertising.
The study was conducted through the Center
for Chronic Conditions of Childhood, a clini-
cal research facility at Rainbow Babies and
Children’s Hospital. The Institutional Review
Board of University Hospitals of Cleveland
approved the study protocol, and written
informed consent was obtained from parents.
Children were eligible if they were between 2
and 17 years of age at the time of recruitment,
had physician-diagnosed asthma for at least
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OBJECTIVE: Home dampness and the presence of mold and allergens have been associated with
asthma morbidity. We examined changes in asthma morbidity in children as a result of home reme-
diation aimed at moisture sources. 
DESIGN: In this prospective, randomized controlled trial, symptomatic, asthmatic children (n = 62),
2–17 years of age, living in a home with indoor mold, received an asthma intervention including an
action plan, education, and individualized problem solving. The remediation group also received
household repairs, including reduction of water inﬁltration, removal of water-damaged building
materials, and heating/ventilation/air-conditioning alterations. The control group received only
home cleaning information. We measured children’s total and allergen-specific serum immuno-
globulin E, peripheral blood eosinophil counts, and urinary cotinine. Environmental dust samples
were analyzed for dust mite, cockroach, rodent urinary protein, endotoxin, and fungi. The follow-up
period was 1 year. 
RESULTS: Children in both groups showed improvement in asthma symptomatic days during the
preremediation portion of the study. The remediation group had a signiﬁcant decrease in symptom
days (p = 0.003, as randomized; p = 0.004, intent to treat) after remodeling, whereas these parame-
ters in the control group did not signiﬁcantly change. In the postremediation period, the remedia-
tion group had a lower rate of exacerbations compared with control asthmatics (as treated: 1 of 29
vs. 11 of 33, respectively, p = 0. 003; intent to treat: 28.1% and 10.0%, respectively, p = 0.11).
CONCLUSION: Construction remediation aimed at the root cause of moisture sources and combined
with a medical/behavioral intervention signiﬁcantly reduces symptom days and health care use for
asthmatic children who live in homes with a documented mold problem. 
KEY WORDS: asthma, children, damp housing, home remediation, indoor mold. Environ Health
Perspect 114:1574–1580 (2006). doi:10.1289/ehp.8742 available via http://dx.doi.org/ [Online
25 April 2006]3 months before enrollment, were English
speaking (child and caregivers), and had at least
two ED visits or at least one hospitalization for
asthma in the 12 months preceding enroll-
ment. Families were also required to live in
Cuyahoga County and agreed to remain in
their current residence for the 12-month dura-
tion of the study.
Patients were excluded if there was a his-
tory of life-threatening asthma, including his-
tory of respiratory failure, intubation, hypoxic
seizure or anaphylaxis, another respiratory ill-
ness such as cystic ﬁbrosis, or any other chronic
illnesses. Screening for the presence of house-
hold mold was performed by trained sanitari-
ans and conducted during a home survey
before enrolling the family in the program.
Subjects who resided in households in which
no visible mold was identiﬁed during the ﬁrst
environmental visit were also excluded.
Demographic and illness information was
collected on all patients who were approached
for recruitment into the study to determine
eligibility, and application materials were com-
pleted at a ﬁrst screening encounter [environ-
mental visit 0 (EV0)]. Enrolled patients
returned for the ﬁrst study visit [clinical visit 0
(CV0)] and, after signing informed consent,
had baseline study measures recorded (Table 1),
including asthma symptoms, caregiver report
of treatment plan, school asthma management,
family responsibility for asthma, and caretaker
brief symptom inventory. Spirometry was
also obtained.
Using each subject’s reported asthma
symptoms during CV0, a pediatric pulmo-
nologist (C.M.K.) assigned the appropriate
asthma severity category and formulated a
written asthma treatment plan for both base-
line and symptomatic periods, using criteria
set forth in the National Asthma Education
and Prevention Project guidelines (National
Institutes of Health–National Heart, Blood,
and Lung Institute 1997). The written treat-
ment plan was provided to all patients during
the initial study visit. A copy of this written
treatment plan was forwarded to each
enrolled subject’s primary care physician, who
continued to provide asthma care throughout
the study.
All patients received in-depth instruction
on the use of their personalized medical treat-
ment plan, as well as instructions for medica-
tion use, including use of spacer devices with
metered-dose inhalers. During the next study
visit, problem solving issues were discussed,
based on data collected during baseline inter-
views. Barriers to adherence to the asthma
management plan were explored and personal-
ized, and speciﬁc interventions were provided
for the patient and caregiver. A 24-hr tele-
phone hotline, answered by trained nurses or
physicians, was made available to all patients
for questions regarding acute asthma manage-
ment. At the next clinical visit (CV1), 1 month
after baseline, families and children again were
interviewed regarding asthma management
and symptoms, using a standardized data col-
lection instrument based on the Children’s
Health Survey for Asthma (CHSA). The
CHSA was designed, tested, and validated by
the American Academy of Pediatrics to capture
asthma symptoms, morbidity measures, and
quality of life measures (Asmussen et al. 1999).
Spirometry was again performed, and labora-
tory measures [complete blood cell counts,
serum immunoglobulin E (IgE), radioaller-
gosorbent test (RAST), urinary cotinine] were
obtained. These ﬁrst study visits and interven-
tion measures were designed to provide opti-
mized medical care, asthma knowledge, and
management skills to all participants. Within
1 week of clinical evaluation (CV1), a home
visit (EV1) was then performed by trained san-
itarians for the purpose of determining the
extent of household mold and moisture prob-
lems and to determine that remediation was
feasible. A standardized visual assessment tool
was used to score the extent of visible mold
present in multiple areas of the home. Dust
samples were obtained from the child’s bed-
room to measure mold, dust mite, cockroach,
mouse, and rat urine allergens and endotoxin.
Dust was processed and assayed for allergens
and endotoxin using standard methods by IBT
Reference Laboratory (Lenexa, KS). A dust
aliquot was analyzed by quantitative polymerase
chain reaction for 33 fungal species using
species-speciﬁc genomic probes (Vesper et al.
2004). Full details of the home survey proce-
dures are described elsewhere (Environmental
Health Watch 2005).
We calculated geometric means of spore-
equivalent counts per square meter for indoor
and outdoor molds species groups and for all
33 molds. The difference in the log of the geo-
metric means between indoor and outdoor
mold groups was also calculated. The 33 mold
species were divided a priori into primarily
indoor molds (Aspergillus- and Penicillium-
predominant species) and outdoor molds
(Alternaria and Cladisporium-predominant
species). A full list of indoor and outdoor
molds is available from the authors.
Randomization occurred immediately after
EV1 if mold was identiﬁed, and subjects were
stratiﬁed by age of the child, using a random
permuted block scheme that prevented person-
nel from randomizing based on predictions of
the next assignment. Once a child was deter-
mined to be eligible for randomization, study
personnel accessed the program to obtain the
next group assignment. Families randomized to
the remediation group had a home remediation
performed 4–5 months after study entry, after
the extent of the repairs was assessed and a plan
for construction devised (full details described
elsewhere; Environmental Health Watch
2005). Brieﬂy, interventions were directed at
reducing water inﬁltration, removal of water-
damaged building materials, alterations to heat-
ing/ventilation/air conditioning, lead hazard
control, and environmental cleaning. General
strategies included cleaning mold from hard
surfaces, removing mold exposure pathways,
stopping rainwater intrusion, exhausting water
vapor from kitchens and bathrooms, and
repairing plumbing leaks. Specific interven-
tions included repair of faulty cold-air return
to furnace, elimination of subslab heating duct
systems, disconnecting and redirecting down-
spouts, and reducing moisture in crawlspaces
and basements. After satisfactory home remedi-
ation, a date of clearance was issued, and the
family and household entered the remainder of
the follow-up phase of the study. A repeat
home environmental survey for dust sampling
occurred at approximately 6 and 12 months
after randomization (EV2, EV3). However,
because of unforeseen delays in completing
home remediation, some visits were delayed > 6
months after due dates. Families randomized to
the control group were given information on
how to improve home indoor air quality, but
were given no speciﬁc tangible resources, mate-
rials, or advice to do so (Environmental Health
Watch 2005; U.S. Environmental Protection
Agency 2002). At the end of the study, partici-
pants in the control group were given a vacuum
cleaner and offered home remediation. Neither
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Table 1. Study timeline and schedule of measures (days). 
EV0 CV0 PS CV1 EV1 R/C C2 C4 CV2, EV2 C8 C10 CV3, EV3
Visit –30 to 1 11–14 15–30 31–45 52 120–150 150 210 270 330 390 450
Recruitment X
Home mold screen X X
Consent X X
Clinical testing X X X
Spirometry X X X
Home environment X X
Sampling X
Problem solving X
Randomization X
Remediation X
Clearance X
Phone follow-up X X X X
Abbreviations: C, call; PS, problem-solving visit; R/C, remediation/clearance.the study personnel nor the families were
blinded as to group assignment once the inter-
vention was started.
Telephone follow-up calls occurred at 2, 4,
8, and 10 months and follow-up visits at 6 and
12 months after randomization. During phone
follow-up at 2, 4, 8, and 10 months, all sub-
jects had interim asthma symptoms monitored
using an abbreviated version of the CHSA.
Caregivers were asked to recall frequency of
symptoms (days and nights with wheezing,
shortness of breath, cough, and difﬁculty sleep-
ing during the previous 4 weeks). Caregivers
were also asked to recall any hospitalizations,
ED visits, unscheduled ofﬁce visits, and missed
school days during the previous 2 months. At
the follow-up clinical visits (CV2 and CV3),
the children also performed spirometry and
certain laboratory tests. Testing included com-
plete blood cell count with differential; serum
lead concentration on children < 6 years of age;
serum IgE; RAST for molds (Aspergillus,
Alternaria, Penicillium, Stachybotrys), cockroach
(Bla g 1), dust mite (Der p 1, Der f 1), mouse
urine, and rat urine; and urinary cotinine.
Adverse events were noted for all entered
subjects. Expected adverse events were asthma
exacerbations requiring either unscheduled
acute care visits (ED or urgent care) or hospi-
talizations. Any event requiring emergency or
hospital care was recorded. Quarterly review of
adverse events was monitored to assure that
there was no discrepancy between the groups
that may have required stopping the study.
The number of asthma-related acute care visits
(ED visits and hospitalizations) of all subjects
were determined by self-report and conﬁrmed
by a review of hospital records.
Statistical analyses. We compared categori-
cal variables between groups using chi-square
tests, using an exact test when sample sizes
were small. We compared continuous variables
between groups using t-tests or Wilcoxon rank
sum tests. The primary outcome was sympto-
matic days, defined as maximum number of
days when any asthma symptom (cough or
wheeze) or asthma attacks occurred over the
4 weeks preceding the follow-up call or clinical
visit. Secondary outcomes included CHSA
subscale scores, health care use (ED visits and
hospitalizations for asthma), inflammatory
markers (serum and serum IgE), and home
environmental markers (mold). Analyses were
carried out in SAS/STAT software (versions
8.2 and 9.1; SAS Institute Inc. 2004a, 2004b). 
Because of unavoidable circumstances,
three subjects originally randomized to the con-
trol group had home remediation performed
and were included in the analysis as part of the
remediation group; in addition, three subjects
originally randomized to the intervention group
did not have home remediation and were
included in the analyses as control subjects. The
groups are therefore referred to as “as-treated”
to distinguish from as randomized. Data for the
primary outcome and select secondary out-
comes where differences occurred are given for
both “as-treated” and “as-randomized” (intent-
to-treat) analyses.
We used linear mixed-model analyses to
compare symptom days and CHSA subscales.
To better meet the assumptions of normality,
we transformed symptom days by taking the
natural logarithm of symptom days + 1, where
the constant 1 was added to avoid taking the
logarithm of zero. We used a compound sym-
metry covariance structure in ﬁtting the model;
we estimated SEs and tests using an estimated
covariance matrix of parameter estimates that is
robust to misspeciﬁcation of the form of the
covariance structure. Estimated means and
conﬁdence intervals (CIs) from this were trans-
formed back to the original scale. The model
compared as-treated groups across visits, includ-
ing baseline CV0 asthma severity as a baseline
covariate and also adjusting for season of the
year when the visit was held as a time-varying
categorical covariate with four levels [winter
(December–February), spring (March–May),
summer (June–August), fall (September–
November)]. The model also included terms
for visit, group, and group × visit interaction.
Data from baseline and all follow-up visits were
included in the model. A p-value of 0.05 was
considered signiﬁcant.
We calculated the mold score by adding
mold scales across all rooms, which included the
basement, kitchen, TV/living room, bathroom,
child’s bedroom, attic, and other bedroom.
The visible mold scales in each room have four
categories (0, none; 1, < 4 ft2; 2, 4–32 ft2; 3, >
32 ft2). We analyzed changes in mold scores
from EV1 to EV2 using a mixed model,
adjusting for season of the year.
We compared allergen levels and mold
indices determined from dust samples between
remediation groups using the Wilcoxon rank-
sum test at EV1, EV2, and EV3. Changes
from EV1 to EV2 and EV3 were tested within
groups and compared between groups using a
mixed linear model adjusting for season of the
year and type of surface (carpet vs. hard).
The initial recruitment goal was 150 sub-
jects, with 75 in each group, which initial
power calculations indicated would provide
80% power to detect a difference between
groups in the primary outcome of mean
symptom days of 2.3 days per 4-week period
with a two-sided test with α = 0.05.
However, in spite of aggressive recruitment
measures, it was not possible to reach the
required number of subjects.
Results
Study population. There were 366 referrals
made for study recruitment; of these, 261
completed EV0 and 62 were randomized.
Subjects who did not enter the program did
so for a number of reasons: 23.8% (87) had
no mold detected, 4.4% (16) were moving,
23.2% (85) did not complete an application,
and 0.8% (2) landlords refused to participate.
Of the 62 patients enrolled, 82% (26 of 29 in
the as-treated group receiving remediation;
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Table 2. Demographic and immunologic data.
Characteristic Control (n = 33) Remediation (n = 29)
Age [years (mean ± SD) 6.5 ± 3.9 7.1 ± 3.8
Male sex [n (%)] 18 (54.5) 19 (65.6)
Ethnicity [n (%)]
Black/other 23 (71.9) 24 (82.8)
White 9 (28.1) 5 (17.2)
Insurance [n (%)]
Medicaid/self 17 (58.6) 13 (54.1)
Private 12 (41.4) 11 (45.8)
Severity [n (%)]
Intermittent 8 (24.2) 5 (17.2)
Mild 16 (48.5) 14 (48.3)
Moderate 6 (18.2) 6 (20.7)
Severe 3 (9.1) 4 (13.8)
Housing type [n (%)]
Traditional 28 (84.8) 23 (82.1)
Section 8/other 5 (15.2) 5 (17.9)
Number living in home (mean ± SD) 4.4 ± 1.7 4.9 ± 1.6
Roach problem in last year [n (%)] 6 (18.2) 4 (13.8)
Rodent problem in last year [n (%)] 6 (18.2) 4 (13.8)
Pet (any type) in home [n (%)] 14 (43.8) 10 (35.7)
CV1 blood eosinophil % [mean ± SD (n)] 3.8 ± 3.6 (28) 7.2 ± 5.6 (23)*
Serum IgE [log10(total IgE)] baseline [mean ± SD (n)] 2.13 ± 0.77 (26) 2.09 ± 0.78 (22)
Baseline RAST by study group (%)
Any RAST 13/32 (40.6) 18/27 (66.7)
Any mold 10/32 (31.3) 9/27 (33.3)
Cockroach (German) 6/27 (22.2) 4/22 (18.2)
Dermatophagoides pteronyssinus mite 8/31 (25.8) 10/27 (37.0)
Mouse urine 3/29 (10.3) 4/24 (16.7)
Rat urine 3/28 (10.7) 2/23 (8.7)
*p = 0.004, Wilcoxon rank-sum test.25 of 33 in the group without remediation)
completed the study, defined as completing
the CV3 (12-month) visit.
Demographic data are shown in Table 2.
There were no signiﬁcant differences between
the groups with respect to age, race, sex, or
asthma severity. The mean age of the children
was 7 years, and most were African American.
More than 75% of the children had mild to
severe persistent asthma. One-third of the fam-
ilies had an annual income < $20,000, and
> 75% of families in both groups resided in
traditional, single-family housing. Most fami-
lies reported relatively few smokers in the
household, with 73% of the control group
reporting no smokers and 66% of the remedia-
tion group reporting no smokers. Mean (± SD)
urinary cotinine levels measured at baseline
were relatively low in both groups (control,
18.6 ng/mL ± 30.1; remediation, 31.9 ng/mL
± 40.4; p = 0.36). Fewer than 20% of families
reported an obvious problem with roach or
rodent infestation, and fewer than half of the
households kept a pet. Total serum IgE con-
centrations were similar at baseline between the
control and remediation groups, but peripheral
blood eosinophil counts were significantly
higher in the remediation group. There was no
signiﬁcant difference in the IgE levels (log total
IgE IU/mL) or total eosinophil counts between
the ﬁrst and last clinical visits in either the con-
trol or remediation groups (either as random-
ized or as remediated). Examination of RAST
results at baseline showed that there was no dif-
ference in the number of patients with positive
tests to any mold, roach, dust, rat, or mouse
urine. There was a trend for more patients to
have any positive RAST in the remediation
group compared with control, but this did not
reach statistical signiﬁcance. There was no dif-
ference in the reported use of controller med-
ications (inhaled steroids and montelukast)
between the control and remediation groups at
CV1, CV2, or CV3 (data not shown).
Environmental measures. Allergen and
endotoxin concentrations (per square meter)
measured throughout the study are shown in
Table 3. There were no signiﬁcant differences
in any allergen or endotoxin measures at base-
line between the control and remediated
groups. We examined the relationship between
baseline endotoxin levels and the presence of
pets or pests in the home. No correlation
existed between the presence of a pet and
endotoxin levels. However, there was a signiﬁ-
cant correlation between mouse allergen levels
(Spearman r = 0.30, p = 03), but not rat
(Spearman r = 0.23, p = 0.10), and endotoxin.
The mean change in endotoxin concentration
between baseline and the EV2 sample was sig-
niﬁcantly greater in the remediated compared
with the control group; however, the difference
was no longer significant at EV3 (Table 3).
There were no other significant changes in
mean allergen levels between the groups at any
time points. There was a trend toward a greater
reduction in mouse allergen levels in the reme-
diated group compared with control at EV3
and a similar trend toward greater β-glucan
reduction in the control group compared with
remediation at EV3 (data not shown).
Signiﬁcant within-group reduction was seen at
EV3 for mouse urine in the remediated group.
Der p 1 levels were significantly increased at
EV2 in the control group.
Total mold scores were determined from
the visual inspection performed by the sanitari-
ans during the home environmental visits.
Baseline mold scores were not different
between the control and remediation groups.
Total visible mold scores were significantly
lower in the remediation group compared with
the control at both EV2 and EV3 (Table 4).
Finally, the changes in mold scores from base-
line to EV2 and EV3 were greater in the reme-
diation group compared with control, and
approached statistical significance, with the
direction of the change showing greater reduc-
tion in the remediation group.
Change in mold indices (measured as ln
geometric mean of indoor and outdoor molds)
over the course of the intervention was signiﬁ-
cantly greater in the remediation group com-
pared with the control group for indoor but not
outdoor species (Table 5). Although the change
in the ratio of indoor to outdoor mold and the
total fungal load between groups over the inter-
vention period was reduced in the remediation
compared with the control group, the differ-
ence did not reach statistical signiﬁcance.
Asthma symptoms and health care use.
There was no difference in the maximum num-
ber of symptom days reported at baseline in the
two groups. Although subjects in the remedia-
tion group reported fewer symptom days at the
last follow-up visit compared with those in the
control group, the differences did not reach
statistical significance in univariate analyses
(Figure 1). There was a greater reduction in
symptom days in the remediation group com-
pared with the control group when comparing
baseline with CV3; but again, the difference
was not statistically signiﬁcant. However, in the
mixed model analysis adjusted for baseline
asthma severity and season, the remediation
group showed a signiﬁcant reduction in symp-
tom days when comparing baseline with the
10-month follow-up (p = 0.0001), the last visit
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Table 3. Allergen levels from dust samples, by group and study visit.
Mean ± SD (n) Change from baselinea
Allergenb Visit Control Remediation p-Valuec Control Remediated p-Valued
Cockroach  Baseline –1.74 ± 2.13 (27) –1.53 ± 1.72 (26) 0.40
(U/m2) EV2 –1.93 ± 1.60 (17) –1.60 ± 1.64 (22) 0.59 0.38 ± 1.97 0.08 ± 1.73 0.79
EV3 –1.44 ± 2.26 (17) –1.40 ± 1.62 (16) 0.61 0.01 ± 1.78 –0.20 ± 2.22 0.67
Der f 1 (µg/m2) Baseline –1.89 ± 2.94 (27) –2.36 ± 2.63 (26) 0.38
EV2 –2.37 ± 2.90 (17) –2.55 ± 3.00 (22) 0.89 –0.79 ± 3.32 –0.56 ± 1.80 0.40
EV3 –1.65 ± 2.98 (17) –2.49 ± 3.47 (16) 0.61 0.53 ± 3.04 –0.85 ± 2.07 0.12
Der p 1 (µg/m2) Baseline –4.49 ± 2.52 (27) –4.82 ± 2.14 (26) 0.65
EV2 –4.27 ± 2.52 (17) –4.65 ± 2.31 (22) 0.50 0.14 ± 2.20* 0.11 ± 1.68 0.15
EV3 –4.02 ± 1.78 (17) –3.78 ± 2.93 (16) 0.86 0.53 ± 3.04 –0.85 ± 2.07 0.53
Der f 1 + Der p 1 Baseline –1.25 ± 2.80 (27) –2.08 ± 2.49 (26) 0.18
(µg/m2) EV2 –1.91 ± 2.91 (17) –2.27 ± 2.81 (22) 0.67 –0.91 ± 3.07 –0.53 ± 1.60 0.50
EV3 –1.28 ± 2.65 (17) –1.83 ± 3.22 (16) 0.91 0.17 ± 3.16 –0.48 ± 1.98 0.51
Endotoxin Baseline 0.36 ± 2.48 (28) 0.49 ± 1.69 (27) 0.70
(µg/m2) EV2 0.23 ± 2.41 (17) –0.46 ± 2.07 (24) 0.81 0.02 ± 3.67 –0.70 ± 1.80 0.03
EV3 –0.59 ± 1.95 (18) –0.62 ± 2.52 (19) 0.86 –0.41 ± 2.69 –0.76 ± 1.98 0.87
Mouse (ng/m2) Baseline 2.35 ± 1.68 (27) 2.52 ± 0.98 (26) 0.66
EV2 2.39 ± 1.45 (17) 2.05 ± 1.69 (22) 0.48 0.24 ± 1.88 –0.43 ± 1.67 0.14
EV3 2.11 ± 1.70 (17) 1.54 ± 1.99 (16) 0.35 –0.19 ± 1.54 –1.08 ± 1.99** 0.08
Rat (ng/m2) Baseline 0.89 ± 1.63 (27) 1.38 ± 1.21 (26) 0.31
EV2 0.53 ± 1.54 (17) 0.56 ± 1.50 (22) 0.95 –0.90 ± 2.61 –0.83 ± 1.83 0.74
EV3 0.15 ± 1.01 (17) 0.58 ± 1.45 (16) 0.28 –0.85 ± 1.84 –0.96 ± 2.06 0.91
aWithin-group changes signiﬁcantly different from zero (after adjusting for season of the year and surface type) are marked
as follows: *p < 0.05, **p < 0. 01. bValues reported are natural logarithms of values. cWilcoxon rank-sum test. dBetween-
group test comparing mean changes, adjusting for season of the year, and surface type (carpet vs. hard surface).
Table 4. Mold scores [mean ± SD (n)].
Time point Control Remediation p-Valuea
Baseline (EV1) 3.03 ± 1.59 (33) 3.03 ± 2.16 (29) 0.66
6 months (EV2) 2.72 ± 1.99 (18) 1.38 ± 1.75 (26) 0.016
12 months (EV3) 1.68 ± 1.32 (22) 0.75 ± 0.99 (24) 0.009
Change EV2 – EV1 –0.28 ± 2.16 (18) –1.42 ± 2.69 (26) 0.09
Test of changeb 0.56 0.003
Change EV3 – EV1 –1.45 ± 2.02 (22) –2.58 ± 2.10 (24) 0.07
Test of changeb 0.0003 < 0.0001
aBetween-group differences; Wilcoxon rank-sum test at EV1, EV2, EV3; test from mixed model adjusting for season of the
year when comparing changes EV2 – EV1 and EV3 – EV1. bWithin-group differences; p-value for test of whether change is
equal to zero, adjusting for season of the year.(p = 0.05), or the average of the 10-month and
last visit values (p = 0.003) (Figure 2). In the as-
randomized analysis, there were similar and sta-
tistically signiﬁcant reductions from baseline to
10 months (p = 0.0002) and in the average of
the 10-month and ﬁnal values (p = 0.004). The
reduction in symptom days from baseline to the
ﬁnal value (CV3) approached but did not reach
statistical signiﬁcance (p = 0.06). Changes in
symptom days within the control group were
not statistically signiﬁcant.
Over the 12-month follow-up after ran-
domization, 36.4% of controls versus 17.2%
of subjects in the as-remediated group had one
or more acute care visits (p = 0.15, Table 6);
results for the as-randomized analysis were
similar. Focusing on the period from 6 to 12
months postrandomization, which corre-
sponded approximately to the postremediation
period, 28.1% and 10.0% of subjects in the
control and remediation groups (as random-
ized), respectively (p = 0.11), compared with
33.3% and 3.5% (p = 0.003) for the as-treated
groups, had one or more acute care visits.
Thus, although a similar trend existed in the
as-randomized analysis, it was not signiﬁcant
at the 0.05 level. The 11 subjects in the con-
trol group made a total of 17 acute care visits,
compared with two visits made by a single
subject in the remediation group. There was
minimal use of the hotline over the study
duration; eight patients (four control, four
remediation) made a total of 12 calls. Advice
given was to follow action plan for eight calls,
and to contact primary care physician for four
calls. No patient was advised to go directly to
the hospital by the hotline staff.
Pulmonary function data were available on
a limited number of study subjects (n = 33)
largely because of the young age of half the
subjects and inability to perform acceptable
spirometry. There was no difference in any
spirometric measure at CV1 between the
control and remediation groups. At the first
postremediation visit (CV2), forced vital capac-
ity, forced expiratory volume at 1 sec, and peak
expiratory ﬂow rate values were all higher in the
remediation group than in the controls. At the
end of the study (CV3), there was again no sig-
nificant difference in any measure of pul-
monary function between the groups (data not
shown). However, the extremely small sample
size limits the conclusions and increases poten-
tial biases related to these data.
The CHSA measures functional morbidity
in several domains, including asthma symp-
toms (child physical health), activity limitation
of the child and family, and emotional well-
being of both the child and the family. We saw
no difference between the groups for any sub-
scale measurement of the CHSA when com-
paring changes between baseline and CV3
(Figure 3). In the remediated group, there were
signiﬁcant within-group improvements in all
domains, except for child emotional function.
However, in the control group, there was sig-
nificant improvement in only the child and
family emotional domains.
Cost. The mean (± SD) cost of remediation
per household was $3,458 ± $2,795 (median,
$3,182; range, $535–6,550).
Discussion
We developed an intervention designed to
examine the health effects of an environmen-
tal remediation aimed at reducing indoor
mold and moisture for children with persis-
tent asthma. Our sample was largely African
American, and more than a third were indi-
gent; these children represent a high-risk
group for asthma morbidity. In addition,
most were atopic, having at least one positive
RAST result for an indoor allergen.
Because appropriate asthma management
requires actions in several domains, such as
medical care, family and patient education,
management skills, adherence to treatment, and
trigger and allergen avoidance, it was important
to provide participants with adequate skills and
tools in all the above areas to isolate the effects
of the environmental intervention. By provid-
ing subjects in both the remediation and con-
trol groups with a multidisciplinary asthma
intervention that we have used extensively in
previous studies, our data on the effects of the
environmental intervention on asthma morbid-
ity have increased validity.
Previous studies have established the rela-
tionship of home dampness or mold to the
presence of respiratory symptoms, such as bron-
chitis, cough, and other chest illnesses, but
other studies have not (Daisey et al. 2003;
Zureik et al. 2002). In a more recent study,
exposure to household molds early in life was
associated with the development of wheeze and
persistent cough among children with a mater-
nal history of asthma (Belanger et al. 2003).
Some studies (Jaakola et al. 2005; Zock et al.
2002) relied on self-report of household damp-
ness or the presence of mold, and this may have
accounted for some of the variability in results.
In the early phases of our study, we found that
families were highly inaccurate in reporting the
presence of mold, and we quickly adopted a
strategy that permitted study randomization
Kercsmar et al.
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Table 5. Comparison of mold indices between remediated and control groups.
Mean ± SDa Change from baseline estimate (95% CI)b
Mold indexc Visit Control Remediated Control Remediated
Indoor molds Baseline 6.45 ± 1.79 6.31 ± 1.39 — —
EV2 6.21 ± 1.43 5.59 ± 1.74 0.43 (–0.33 to 1.19) –0.57 (–1.21 to 0.07)*
EV3 6.35 ± 1.59 5.81 ± 1.80 0.33 (–0.40 to 1.04) –0.41 (–1.08 to 0.27)
Outdoor molds Baseline 8.79 ± 1.60 9.00 ± 1.17 — —
EV2 8.44 ± 1.50 8.31 ± 1.95 0.23 (–0.72 to 1.17) –0.30 (–1.13 to 0.52)
EV3 8.55 ± 1.83 8.39 ± 1.68 0.15 (–0.52 to 0.82) –0.43 (–1.07 to 0.21)
Indoor:outdoor Baseline –2.34 ± 1.18 –2.69 ± 0.89 — —
ratio EV2 –2.23 ± 1.15 –2.72 ± 1.05 0.24 (–0.31 to 0.78) –0.29 (–0.75 to 0.17)
EV3 –2.20 ± 1.07 –2.59 ± 0.91 0.10 (–0.43 to 0.64) –0.01 (–0.53 to 0.51)
Total fungal Baseline 7.19 ± 1.62 7.07 ± 1.27 — —
load EV2 6.81 ± 1.39 6.40 ± 1.71 0.24 (–0.51 to 1.00) –0.42 (–1.07 to 0.22)
EV3 6.98 ± 1.55 6.54 ± 1.70 0.15 (–0.49 to 0.80) –0.39 (–0.99 to 0.22)
aSample sizes at baseline, EV2, and EV3 are 27, 18, and 18 for control and 26, 24, and 18 for remediated. bEstimates are
adjusted for season and surface type (carpet vs. hard surface) in a mixed linear regression model. cMold indices are
deﬁned as follows: Indoor molds = ln(geometric mean of indoor molds in cfu/m2). Outdoor molds = ln(geometric mean of
outdoor molds in cfu/m2). Indoor:outdoor ratio = ln(geometric mean of indoor molds/geometric mean of outdoor molds) =
ln(geometric mean of indoor molds in cfu/m2) – ln(geometric mean of outdoor molds in cfu/m2). Total fungal load =
ln(geometric mean of indoor and outdoor molds, in cfu/m2). See “Materials and Methods” for complete list of indoor and
outdoor molds. *Differs from control group, p < 0.05.
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Figure 1. Unadjusted mean maximal symptom days
± 1 SE for control group and remediation group. 
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Figure 2. Mean maximal symptom days over study
duration for control and remediation groups. Values
are means and 95% CIs estimated from a mixed
model, adjusting for baseline asthma severity and
season of the year. In the remediation group, maxi-
mal symptom days decreased significantly from
baseline at 10 months (p < 0.0001) and at CV3 (p =
0.053), whereas the changes from baseline in the
control group at these time points were not statisti-
cally significant. Changes from baseline at 10
months and at CV3 did not differ significantly
between control and remediated groups.only after a direct home inspection conﬁrmed
the presence of mold. In addition, we used a
visual assessment tool applied by a trained sani-
tarian to quantify the extent of mold present in
the household.
Almost a third of subjects in each group
had a positive RAST result for any mold.
Moreover, 20% had a positive RAST for cock-
roach and > 25% for dust mite. The availability
of water sources promotes the survival and
reproduction of roaches, whereas high levels of
indoor humidity are associated with dust mite
and mold proliferation. Although outdoor
molds can also be ampliﬁed with indoor damp
conditions, the failure of the remediation to sig-
niﬁcantly reduce these molds may indicate that
mold was tracked in from outdoors. The base-
ment was most commonly the largest source of
mold in the houses; therefore, the exclusion of
basement air from the living space ventilation
in 38% of the remediated homes likely con-
tributed to the decrease in the amount of
indoor molds in the children’s bedroom dust.
Our data suggest that in homes with a doc-
umented mold problem, a construction remedi-
ation aimed at the root cause of the moisture
sources signiﬁcantly reduces symptomatic days
for the asthmatic children living in those homes
compared with asthmatic children living in
homes without a mold remediation. Symptom
days slightly decreased in both groups in the
interval before remediation, suggesting an
effect of the global intervention provided to
both groups and/or regression to the mean.
However, in the interval after remediation and
by 10 months after study entry, subjects in the
remediation group showed a signiﬁcant reduc-
tion in maximum symptom days compared
with baseline, whereas the control group did
not. This symptom reduction persisted
through the last study visits. In addition, there
was also a marked reduction in ED visits and
hospitalizations for asthma in the remediation
group compared with the control group.
Although acute care visits for asthma are rela-
tively infrequent events, they are costly, disrup-
tive, and harmful for children and families.
Pulmonary function was also improved by
CV2 in the remediation group but not in the
controls; although promising, these data are
limited by the relatively small number of
participants who completed the tests.
Home remediation for environmental
allergens and irritants has met with mixed
success in previous studies. The National
Cooperative Inner City Asthma Study applied
medical, psychosocial, and environmental
interventions in an attempt to decrease asthma
morbidity in urban-living, school-age asth-
matic children. A signiﬁcant decrease in symp-
tomatic days and health care visits was
documented; however, no signiﬁcant reduction
in home environmental allergens and irritants
(dust, cockroach) occurred, and only half of
the enrollees obtained asthma treatment plans
(Evans et al. 1999; Gergen et al. 1999). More
recently, the Inner City Asthma Study demon-
strated that an intensive, customized home
intervention that included provision of pillow
and mattress dust covers, room HEPA ﬁlters,
vacuum cleaners, and integrated pest manage-
ment services resulted in a decrease in indoor
dust and roach allergen levels and a signiﬁcant
reduction in days with wheeze over a 2-year
follow-up (Crain et al. 2002; Morgan et al.
2004). No structural repairs were conducted.
Prior cockroach abatement programs used
professional exterminators or an integrated pest
management program to reduce roach allergen
levels. Although professional extermination
coupled with clean-up instructions for the fam-
ily was not successful in signiﬁcantly reducing
roach allergen levels, the integrated pest man-
agement strategy was beneficial (Eggleston
et al. 1999; Rosenstreich et al. 1997). The lat-
ter did involve removing water sources, such as
plumbing leaks.
Compared with previous studies, our inter-
vention took a more global approach to
addressing root cause of home water damage
and moisture sources that contribute to mold,
roach, and dust mite problems. In addition, any
moldy materials were removed from the homes
during the remediation process. These types of
repairs are often outside the ﬁnancial resources
of many families and are often ignored by land-
lords. We demonstrated a signiﬁcant reduction
in mold scores in the remediated homes com-
pared with the control homes (Tables 4 and 5)
using interventions of rather modest expense.
These data support the relationship between
reduction in home mold and moisture and
improvement in asthma symptoms.
Our study has several limitations. First, the
sample size was far lower than that required by
our original study design and power analysis.
Failure to recruit adequate numbers of families
occurred for a number of reasons, such as the
frequency with which inner-city families relo-
cate and unwillingness to participate by land-
lords and, to a lesser extent, homeowners. The
application process required a number of steps
to complete and documents to produce (e.g.,
proof of home ownership, tax bills) that may
have been too complex or invasive for some
families. Because our sample size was relatively
small, these data should be regarded as
exploratory, and larger trials will be needed to
confirm our results. Nevertheless, we believe
the data strongly indicate that mold and mois-
ture reduction are feasible and, when combined
with other asthma intervention measures, can
further reduce asthma morbidity in children.
Further data analyses on the relationship of spe-
ciﬁc fungi to asthma symptoms are also being
conducted and will be reported elsewhere. A
detailed cost analysis of the program will also
need to be completed to help better guide the
cost-effectiveness of the program. Although our
data suggest that the home remediation remains
intact and effective for at least a year after com-
pletion, it will be important to continue to
maintain homes free from excessive moisture
sources to prevent return of mold problems.
Finally, other factors not obviously measured in
our study besides reduction of household mold
could have contributed to the improvement in
asthma symptoms seen in the remediation
group. Families in this group may have taken
other steps to improve the indoor environment
or otherwise improve the asthma care provided
to their children as a result of being in the
Home moisture remediation for childhood asthma
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Table 6. ED visits and hospitalizations during follow-up.
Control Remediation
Time period Outcome (n = 33) (n = 29) p-Value
Entire 12 months of follow-up ≥ 1 ED or inpatient visits [n (%)] 12 (36.4) 5 (17.2) 0.15
No. of ED/inpatient visits (mean ± SD) 0.91 ± 1.79 0.28 ± 0.80 0.06
From 6 months postrandomization ≥ 1 ED or inpatient visits [n (%)] 11 (33.3) 1 (3.5) 0.003
to end of follow-up No. of ED/inpatient visits (mean ± SD) 0.52 ± 0.83 0.07 ± 0.37 0.004
p-Value from Fisher’s exact test or exact Wilcoxon rank-sum test.
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Figure 3. Changes from baseline to CV3 in CHSA subscales. Values are means and 95% CIs estimated from
a mixed model, adjusting for baseline asthma severity and season of the year. p-Values above the x-axis,
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remediation group. Although the participants
in both groups received the same degree of
asthma intervention in terms of education,
treatment plan, and problem solving, the con-
trol group subjects may have sought additional
outside help for asthma or home remediation.
In summary, we have demonstrated in this
small study the feasibility of performing suc-
cessful home remediation for mold and mois-
ture and the resultant improvement in asthma
morbidity associated with reduction in indoor
mold. We believe these data are strong enough
to warrant further studies on home mold reme-
diation to improve the health of children with
respiratory conditions. Future studies, particu-
larly with inner-city populations, will need to
use streamlined, simple recruitment and entry
criteria to ensure that those in greatest need
participate.
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